Integra Lifesciences Holdings Corp (IART) FinancialsIARTIntegra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation (IART) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Neurosurgery, accounting for 50.9% of total sales, equivalent to $213.26M. Other significant revenue streams include Wound Reconstruction and Care and Instruments. Understanding this composition is critical for investors evaluating how IART navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Integra LifeSciences Holdings Corporation maintains a gross margin of 54.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.86%, while the net margin is 1.07%. These profitability ratios, combined with a Return on Equity (ROE) of -0.70%, provide a clear picture of how effectively IART converts its operational activities into shareholder value.

In the context of the broader market, IART competes directly with industry leaders such as CSTL and PRCT. With a market capitalization of $1.08B, it holds a significant position in the sector. When comparing efficiency, IART's gross margin of 54.90% stands against CSTL's 74.94% and PRCT's 66.01%. Such benchmarking helps identify whether Integra LifeSciences Holdings Corporation is trading at a premium or discount relative to its financial performance.

Integra Lifesciences has shown mixed financial performance, with Q2 2026 revenue of $418.8 million, which was flat year-over-year. The gross margin has fluctuated, recently reported at 54.90%, and the company has faced net income losses in several quarters, including a net loss of $4.6 million in Q1 2026.